Compare MetLife Inc. Common Stock (MET) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MetLife Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? MetLife Inc. Common Stock trades at $102.41 (market cap $63.96B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: MetLife Inc. Common Stock is far larger — about 8.5× Spyre Therapeutics Inc. Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.35% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MetLife Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MET | SYRE | |
|---|---|---|
Market Cap | $63.96B | $7.52B |
Volume | 3,016,459 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $100.65 | $108.92 |
52-Week Low | $67.70 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $84.89B | $6.52B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MetLife (MET) trades at $100.65, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with a P/E of 19.28 and a net income margin of 4.66%. Recent news highlights a declared dividend of $0.59 per share and upcoming Q3 2026 results.
The outlook for MET is positive, driven by earnings momentum and a favorable interest rate environment for insurers. Key risks include investment income volatility and competitive pressures. With a consensus price target of $108.25 and no sell ratings, Wall Street sentiment remains bullish, though the stock's RSI suggests potential near-term overbought conditions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MetLife Inc. Common Stock
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
